Department of Pathology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
1Department of Pathology, CHA Gangnam Medical Center, CHA University, Seoul, Korea
2Department of Pathology, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
© 2017 The Korean Society of Pathologists/The Korean Society for Cytopathology
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Parameter | Control group | Study group | p-value |
---|---|---|---|
Sex (man:woman)a | 14:65 (18:82) | 8:40 (17:83) | 1.000b |
Age, mean (range, yr)a | 49 (24–75) | 45 (24–68) | .258c |
Man | 50 (32–75) | 54 (41–68) | |
Woman | 47 (24–70) | 44 (24–64) | |
Turnaround time (min)d | |||
Mean | 24 | 57 | .000b |
< 40 min | 84 (98) | 17 (32) | |
≥ 40 min | 2 (2) | 36 (68) | |
Frozen diagnosisd | .149b | ||
Benign | 23 (27) | 12 (23) | |
AH | 20 (23) | 8 (15) | |
LT | 3 (4) | 4 (7) | |
Malignancy | 52 (60) | 35 (66) | |
PTC, conventional | 43 (50) | 29 (55) | |
FVPTC | 7 (8) | 4 (7) | |
PTC, oncocytic variant | 1 (1) | 0 | |
HC | 0 | 1 (2) | |
FC | 1 (1) | 1 (2) | |
Follicular neoplasm | 5 (6) | 6 (11) | |
Deferred | 6 (7) | 0 |
Values are presented as number (%), unless otherwise indicated.
AH, adenomatous hyperplasia; LT, lymphocytic thyroiditis; PTC, papillary thyroid carcinoma; FVPTC, follicular variant papillary thyroid carcinoma; HC, Hurthle cell carcinoma; FC, follicular carcinoma, minimally invasive.
aNumber of patients: control (n = 79), study group (n = 48);
bFisher exact test;
ct test;
dNumber of nodules: control (n = 86), study group (n = 53).
AH, adenomatous hyperplasia; LT, lymphocytic thyroiditis; PTCc, papillary thyroid carcinoma, conventional; FVPTC, follicular variant papillary thyroid carcinoma; cap+, capsule present; inv-, no capsule invasion; inv+, capsule invasion present; cap-, no capsule; HC, Hurthle cell carcinoma; FC, follicular carcinoma, minimally invasive.
FN at frozen diagnosis (No. of nodules) |
Permanent diagnosis (No. of nodules) |
Malignancy rate | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Follicular neoplasm |
Other |
||||||||||
Benign |
Malignant |
Total | AH | PTCo | FVPTC cap+, inv- | FVPTC cap+, inv+ | Total | ||||
FA | HA | HC | FC | ||||||||
Control group (n = 5) | 1 | 0 | 1 | 1 | 3 (60) | 0 | 0 | 1 | 1 | 2 (40) | 0.800 |
Study group (n = 6) | 2 | 1 | 0 | 0 | 3 (50) | 1 | 1a | 1a | 0 | 3 (50) | 0.333 |
Values are presented as number (%).
FN, follicular neoplasm; FA, follicular adenoma; HA, hurthle cell adenoma; HC, hurthle cell carcinoma; FC, follicular carcinoma, minimally invasive; AH, adenomatous hyperplasia; PTCo, oncocytic variant of papillary thyroid carcinoma; FVPTC, follicular variant of papillary thyroid carcinoma; cap+, tumor capsule present; inv-, no capsule invasion; inv+, capsule invasion present.
aAlthough it showed CD56 positivity and cytokeratin 19 (CK19) negativity on rapid immunohistochemical stain of frozen section, focal loss of CD56 and focal reactivity of CK19 were revealed on permanent section of remained lesion.
FA, follicular adenoma; HA, hurthle cell adenoma; AH, adenomatous hyperplasia; PTCo, oncocytic variant of papillary thyroid carcinoma; FVPTC, follicular variant of papillary thyroid carcinoma; cap+, tumor capsule present; inv-, no capsule invasion; inv+, capsule invasion present; HC, hurthle cell carcinoma; FC, follicular carcinoma, minimally invasive.
Immunophenotype |
Permanent diagnosis (No. of nodules) |
Total No. of nodules (n = 36) | ||||||||
---|---|---|---|---|---|---|---|---|---|---|
Benign (n = 15) |
Malignant (n = 21) |
|||||||||
AH | LT | FA | HA | FC | HC | PTCc | PTCo | FVPTC | ||
CK19+/CD56+ | 6 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 9 |
CK19–/CD56+ | 3 | 0 | 2 | 1 | 1 | 1 | 0 | 0 | 0 | 8 |
CK19+/CD56– | 0 | 0 | 0 | 0 | 0 | 0 | 15 | 1a | 3a | 19 |
CK19–/CD56– | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
AH, adenomatous hyperplasia; LT, lymphocytic thyroiditis; FA, follicular adenoma; HA, hurthle cell adenoma; FC, follicular carcinoma, minimally invasive; HC, hurthle cell carcinoma; PTCc, papillary thyroid carcinoma, conventional; PTCo, oncocytic variant of papillary thyroid carcinoma; FVPTC, follicular variant of papillary thyroid carcinom.
aAlthough it showed CD56 positivity and cytokeratin 19 (CK19) negativity on rapid immunohistochemical stain of frozen section, focal loss of CD56 and focal reactivity of CK19 were revealed on permanent section of remained lesion.
Parameter | Control group | Study group | p-value |
---|---|---|---|
Sex (man:woman) |
14:65 (18:82) | 8:40 (17:83) | 1.000 |
Age, mean (range, yr) |
49 (24–75) | 45 (24–68) | .258 |
Man | 50 (32–75) | 54 (41–68) | |
Woman | 47 (24–70) | 44 (24–64) | |
Turnaround time (min) |
|||
Mean | 24 | 57 | .000 |
< 40 min | 84 (98) | 17 (32) | |
≥ 40 min | 2 (2) | 36 (68) | |
Frozen diagnosis |
.149 |
||
Benign | 23 (27) | 12 (23) | |
AH | 20 (23) | 8 (15) | |
LT | 3 (4) | 4 (7) | |
Malignancy | 52 (60) | 35 (66) | |
PTC, conventional | 43 (50) | 29 (55) | |
FVPTC | 7 (8) | 4 (7) | |
PTC, oncocytic variant | 1 (1) | 0 | |
HC | 0 | 1 (2) | |
FC | 1 (1) | 1 (2) | |
Follicular neoplasm | 5 (6) | 6 (11) | |
Deferred | 6 (7) | 0 |
Frozen diagnosis (No. of nodules) | Permanent diagnosis (No. of nodules) |
Discrepancy rate | |||||||
---|---|---|---|---|---|---|---|---|---|
Benign |
Malignant |
||||||||
AH | LT | PTCc | FVPTC cap+, inv- | FVPTC cap+, inv+ | FVPTC cap- | HC | FC | ||
Control group | |||||||||
Benign (n = 23) | 0.087 | ||||||||
AH | 19 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | |
LT | 0 | 2 | 0 | 1 | 0 | 0 | 0 | 0 | |
Malignant (n = 52) | 0.019 | ||||||||
PTCc | 0 | 1 | 38 | 0 | 1 | 2 | 1 | 0 | |
FVPTC | 0 | 0 | 0 | 0 | 0 | 6 | 0 | 1 | |
HC | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
FC | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | |
Study group | |||||||||
Benign (n = 12) | 0 | ||||||||
AH | 8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
LT | 0 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | |
Malignant (n = 35) | 0 | ||||||||
PTCc | 0 | 0 | 29 | 0 | 0 | 0 | 0 | 0 | |
FVPTC | 0 | 0 | 0 | 1 | 3 | 0 | 0 | 0 | |
HC | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | |
FC | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
FN at frozen diagnosis (No. of nodules) | Permanent diagnosis (No. of nodules) |
Malignancy rate | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Follicular neoplasm |
Other |
||||||||||
Benign |
Malignant |
Total | AH | PTCo | FVPTC cap+, inv- | FVPTC cap+, inv+ | Total | ||||
FA | HA | HC | FC | ||||||||
Control group (n = 5) | 1 | 0 | 1 | 1 | 3 (60) | 0 | 0 | 1 | 1 | 2 (40) | 0.800 |
Study group (n = 6) | 2 | 1 | 0 | 0 | 3 (50) | 1 | 1 |
1 |
0 | 3 (50) | 0.333 |
Frozen diagnosis (deffered) | Permanent diagnosis (No. of nodules) |
Malignancy rate | |||||||
---|---|---|---|---|---|---|---|---|---|
Benign (n = 2) |
Malignant (n = 4) |
||||||||
FA | HA | AH | PTCo | FVPTC cap+, inv- | FVPTC cap+, inv+ | HC | FC | ||
Control group | 1 | 0 | 1 | 0 | 4 | 0 | 0 | 0 | 0.667 |
Study group | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Immunophenotype | Permanent diagnosis (No. of nodules) |
Total No. of nodules (n = 36) | ||||||||
---|---|---|---|---|---|---|---|---|---|---|
Benign (n = 15) |
Malignant (n = 21) |
|||||||||
AH | LT | FA | HA | FC | HC | PTCc | PTCo | FVPTC | ||
CK19+/CD56+ | 6 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 9 |
CK19–/CD56+ | 3 | 0 | 2 | 1 | 1 | 1 | 0 | 0 | 0 | 8 |
CK19+/CD56– | 0 | 0 | 0 | 0 | 0 | 0 | 15 | 1 |
3 |
19 |
CK19–/CD56– | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Values are presented as number (%), unless otherwise indicated. AH, adenomatous hyperplasia; LT, lymphocytic thyroiditis; PTC, papillary thyroid carcinoma; FVPTC, follicular variant papillary thyroid carcinoma; HC, Hurthle cell carcinoma; FC, follicular carcinoma, minimally invasive. Number of patients: control (n = 79), study group (n = 48); Fisher exact test; t test; Number of nodules: control (n = 86), study group (n = 53).
AH, adenomatous hyperplasia; LT, lymphocytic thyroiditis; PTCc, papillary thyroid carcinoma, conventional; FVPTC, follicular variant papillary thyroid carcinoma; cap+, capsule present; inv-, no capsule invasion; inv+, capsule invasion present; cap-, no capsule; HC, Hurthle cell carcinoma; FC, follicular carcinoma, minimally invasive.
Values are presented as number (%). FN, follicular neoplasm; FA, follicular adenoma; HA, hurthle cell adenoma; HC, hurthle cell carcinoma; FC, follicular carcinoma, minimally invasive; AH, adenomatous hyperplasia; PTCo, oncocytic variant of papillary thyroid carcinoma; FVPTC, follicular variant of papillary thyroid carcinoma; cap+, tumor capsule present; inv-, no capsule invasion; inv+, capsule invasion present. Although it showed CD56 positivity and cytokeratin 19 (CK19) negativity on rapid immunohistochemical stain of frozen section, focal loss of CD56 and focal reactivity of CK19 were revealed on permanent section of remained lesion.
FA, follicular adenoma; HA, hurthle cell adenoma; AH, adenomatous hyperplasia; PTCo, oncocytic variant of papillary thyroid carcinoma; FVPTC, follicular variant of papillary thyroid carcinoma; cap+, tumor capsule present; inv-, no capsule invasion; inv+, capsule invasion present; HC, hurthle cell carcinoma; FC, follicular carcinoma, minimally invasive.
AH, adenomatous hyperplasia; LT, lymphocytic thyroiditis; FA, follicular adenoma; HA, hurthle cell adenoma; FC, follicular carcinoma, minimally invasive; HC, hurthle cell carcinoma; PTCc, papillary thyroid carcinoma, conventional; PTCo, oncocytic variant of papillary thyroid carcinoma; FVPTC, follicular variant of papillary thyroid carcinom. Although it showed CD56 positivity and cytokeratin 19 (CK19) negativity on rapid immunohistochemical stain of frozen section, focal loss of CD56 and focal reactivity of CK19 were revealed on permanent section of remained lesion.